Mast cells are key mediators of cathelicidin-initiated skin inflammation in rosacea. by Muto, Yumiko et al.
UC San Diego
UC San Diego Previously Published Works
Title
Mast cells are key mediators of cathelicidin-initiated skin inflammation in rosacea.
Permalink
https://escholarship.org/uc/item/7jw2r9mg
Journal
Journal of Investigative Dermatology, 134(11)
Authors
Muto, Yumiko
Wang, Zhenping
Vanderberghe, Matthieu
et al.
Publication Date
2014-11-01
DOI
10.1038/jid.2014.222
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
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inflammation in rosacea
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Anna Di Nardo
Division of Dermatology, Department of Medicine, University of California, San Diego
Abstract
Rosacea is a chronic inflammatory skin disease whose pathophysiological mechanism is still 
unclear. However, it is known that mast cell (MC) numbers is increased in the dermis of rosacea 
patients. MC proteases not only recruit other immune cells, which amplify the inflammatory 
response, but also cause vasodilation and angiogenesis. MCs are also one of the primary sources 
of cathelicidin LL-37 (Cath LL-37), an antimicrobial peptide that has been shown to be an enabler 
of rosacea pathogenesis. Here, we demonstrate that MCs are key mediators of cathelicidin initiated 
skin inflammation. Following Cath LL-37 injection into the dermis, MC deficient B6.Cg-KitW-sh/
HNihrJaeBsmJ (KitW-sh) mice did not develop rosacea-like features. Conversely, chymase 
(p<0.001), tryptase and Mmp9 (p<0.01) mRNA levels were significantly higher in C57BL/6 Wild 
Type (WT) mice. Treating WT mice with a MC stabilizer significantly decreased the expressions 
of Mmp9 and Cxcl2 (p<0.01). Our data was confirmed on Erythematotelangiectatic rosacea 
subjects that showed a decrease in MMP activity (p<0.05), after eight weeks of topical cromolyn 
treatment.
We conclude that MCs play a central role in the development of inflammation subsequent to Cath 
LL-37 activation and that down regulation of activated MCs may be a therapy for rosacea 
treatment.
INTRODUCTION
Rosacea is a chronic inflammatory skin disease that affects ~16 million Americans (The 
National Rosacea Society website). Flares often occur without specific triggers, and when 
left untreated, can take weeks to subside (Scharschmidt et al., 2010). The formation of an 
aberrant form of antimicrobial peptide, Cath LL-37, on the surface of the skin, has been 
previously implicated as a key initiator of rosacea (Yamasaki et al., 2007). Cath LL-37 in 
the skin is also implicated in a wide range of inflammatory diseases including atopic 
dermatitis (Ong et al., 2002) and psoriasis (Lande et al., 2007). The active form of 
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cathelicidin LL-37 peptide is not only able to kill microbes, but also modify host immunity 
and growth responses by promoting leukocyte chemotaxis (De et al., 2000), angiogenesis 
(Koczulla et al., 2003), and can alter the expression of extracellular matrix components 
(Park et al., 2009). In rosacea, the formation of an aberrant form of Cath LL-37 on the 
surface of the skin has been attributed to the overactivity of the kallikrein-related peptidases 
(KLKs), which are a family of tryptic serine proteases that are responsible for generating 
Cath LL-37 from its precursor protein, hCAP18, in the epidermis (Yamasaki et al., 2007) 
(Yamasaki and Gallo, 2008). In an animal model, intradermal injection of Cath LL-37, but 
not mouse cathelicidin, induced an inflammatory response with rosacea-like features 
(Yamasaki et al., 2007). Interestingly, sub-antimicrobial doses (40 mg/day) of doxycycline, 
a proven treatment for human rosacea, directly inhibits matrix metalloproteinases, which in 
turn, inhibits the activity of KLKs and prevents the activation of cathelicidins in human 
epidermal keratinocytes (Korting and Schollmann, 2009) (Kanada et al., 2012). Therefore, 
Cath LL-37 has emerged as a key mediator in the pathogenesis of rosacea.
Many studies have proven that MCs are able to enhance host defense through direct effects 
on pathogens by initiating the inflammation associated with innate immune responses (Galli 
et al., 2008). Although MCs can contribute to overall host protection by releasing a variety 
of molecules, including TNF-α (McLachlan et al., 2008), leukotriene B4 (Malaviya and 
Abraham, 2000), and cathelicidin AMP (Di Nardo et al., 2003), accumulated studies have 
also specifically implicated MCs in the development of inflammation in the skin (Kawakami 
et al., 2009) (Lin et al., 2011) (Thurmond et al., 2008). Most importantly in the context of 
our study, MCs have been observed in increased numbers in the skin lesions of rosacea 
patients. Until now, however, there has been no clear proof of the direct connection between 
MCs and rosacea formation.
In addition to inflammation, neuronal dysregulation is equally important to rosacea 
pathogenesis. In fact, neuronal dysregulation contributes to the disease via various 
mechanisms, such as vasomotor instability, release of pro-inflammatory neuropeptides, and 
neuronal injury (Wang et al., 2008) (Roosterman et al., 2006). MCs can also be activated by 
neuropeptides to release their components upon cell degranulation. Neuropeptides have also 
been shown to induce the production of TNF-α, CCL2, CCL5, CXCL9, CXCL10, and 
CXCL8 in human mast cells (Kulka et al., 2008), which leads to the recruitment of dendritic 
cells/macrophages (via CCL2), TH1 lymphocytes (via CCL5, CXCL9, or CXCL10) and 
neutrophils (via CXCL8) (Gangavarapuet al., 2012). In the current study, we show that 
neuropeptides induce MC enzyme activation and subsequent Cath LL-37 generation from 
hCAP18. Based on these results, it is likely that MCs are mediators of the stress-response 
network in skin inflammation (Arck et al., 2006). Considering previous studies of the role of 
MCs in rosacea, we propose that MCs and MC proteases have critical functions during the 
development of skin inflammation in rosacea. Furthermore, understanding the in vivo 
connections between MCs, epidermal keratinocytes and sensory nerves respectively, may 
lead to a better interpretation of the pathophysiology of rosacea.
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Results
MC deficient mice do not develop inflammation following Cath LL-37 injection in the skin
To verify that MC proteases are increased in rosacea skin, biopsies from 6 rosacea patients 
and 6 healthy control volunteers were collected and CMA1 (chymase gene) and MMP9 
(metallo protease 9 gene) mRNA expressions were measured as essential markers of MC 
presence and activation (Tchougounova et al., 2005). Both CMA1 and MMP9 mRNA levels 
showed significant increases in rosacea skin (n=6) compared with healthy skin (n=6) (Figure 
1a).
Meaning that MCs were abnormally activated and were specifically expressing enzymes 
involved in Cath LL-37 processing.
To prove that MCs are central to the pathogenesis of rosacea inflammation, we used a well-
established mouse model of rosacea-like inflammation (Yamasaki et al., 2007). We injected 
Cath LL-37 intradermally into MC deficient mice B6.Cg-KitW-sh/HNihrJaeBsmJ (KitW-sh) 
and compared the resulting inflammation with Wild Type (WT) mice. Our clinical end point 
observation (at 72hrs) showed, as previously described, inflammation in the skin of WT 
mice injected with Cath LL-37, whereas KitW-sh mice did not develop any rosacea-like 
features (Figure 1b). In order to further establish the essential role of MCs in the observed 
phenotype, we reconstituted the MC deficient mice with wild type MCs and repeated the 
injections with Cath LL-37. To define the specificity of Cath LL-37 in MC activation, we 
also included a Cath LL-37 scrambled peptide in the experiments. Our results showed that, 
following Cath LL-37 challenge, Mmp9 mRNA expression in skin from MC deficient mice 
was significantly lower than in skin from WT (p<0.01) and WT MC-reconstituted KitW-sh 
mice (p<0.05). There was no significant difference observed between any of the mouse 
groups when Cath LL-37 scrambled peptide was used (Figure 1c). We also injected different 
concentrations (50 μM and 320 μM) of Cath LL-37 peptide into WT mice and demonstrated 
that Cath LL-37 induced an increase in MMP activity in a dose dependent manner in WT 
mice (Figure 1d). Furthermore, a time course experiment showed that mRNA of the MC 
specific proteases chymase and tryptase were expressed immediately after injection of Cath 
LL-37, while the same enzymes were not detectable in the skin of the MC-deficient mice 
(Figure 1e).
Mouse MCs (mMCs) release of MMP-9 and IL-6 in response to Cath LL-37
To confirm that MCs are responsive to direct Cath LL-37 stimulation, bone marrow derived 
mouse MCs (mMCs) were stimulated with different concentrations of Cath LL-37 at 
different time points. Mmp9, Cma1 (the gene for Chymase) and Tpsab1 (the gene for 
Tryptase) mRNA expressions were significantly higher at 5 hrs (p<0.001) (Figure 2a), while 
Mmp-1a, Klk5, and Klk6 were not detectable at 5 hrs (data not shown). There were no 
differences in MMP9, Cma1 and Tpsab1 mRNA expressions with different Cath LL-37 
concentrations at 24 hrs (data not shown). MMP-9 protease activity in the culture medium of 
MCs stimulated with Cath LL-37 for 24 hrs was confirmed by fluorescence enzymatic 
activity assay using an MMP specific substrate and an MMP-9 specific inhibitor (Figure 2b). 
In Figure 2b, the difference between the two curves indicates MMP-9 specific activity. MC 
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degranulation was confirmed by measuring β-hexosaminidase release in Cath LL-37 
stimulated MC supernatants. We also found that a very low concentration of Cath LL-37 
(20nM) was enough to induce degranulation (Figure 2c). In addition, ELISA detected high 
levels of secreted IL-6 in mMCs after 24 and 48 hrs of stimulation with different Cath 
LL-37 concentrations (20 nM and 40 nM) (Figure 2d). IL-6 increase was also confirmed in 
vivo. In fact, Il6 mRNA expression was also observed in the skin from WT mice, but not in 
MC deficient mice, following Cath LL-37 challenge (Figure 2e).
Neuropeptides activate tryptic-MC serine proteases in WT mouse skin
Rosacea flare-ups are frequently initiated by face flushing due to neuronal dysfunction and 
increased release of pituitary adenylate cyclase-activating peptide (PACAP) (Schwab et al., 
2011). To investigate whether neuropeptides (NPs) require MC activation for the 
development of the inflammatory response in rosacea, 100μL of 1 μM NPs (substance P: SP; 
adrenomedullin-2: ADM-2; Pituitary adenylate cyclase-activating peptide: PACAP) were 
injected intradermally into WT and MC deficient mice. After 6 hours from the NP 
challenge, skin biopsies were taken and processed for mRNA expression analysis. Tryptase 
mRNA expression was observed to be dramatically increased by PACAP stimulation 
(p<0.01) in WT mice. Cma1, Tpsab1, Mmp1a and Mmp9 were also significantly increased 
(p<0.05) in WT mice (Figure 2f) but not as substantially as PACAP. In addition, mRNA 
expressions of the pro-inflammatory cytokines Cxcl2 (mouse homolog of human IL8) and 
Tnf (gene for TNF-α) were also significantly increased with PACAP challenge in WT mice, 
but not in MC deficient mice (p<0.01) (Figure 2g). These results prove that neurovascular 
alteration and neuropeptide release during a face flushing can be translated to rosacea 
inflammation in skin through the activation of MC enzymes. Moreover, these same MC 
enzymes can further increase the levels of free Cath LL-37 and amplify the inflammatory 
response.
MC stabilizer suppresses the development of rosacea-like inflammation in vivo
According to the obtained results, MC proteases and MMP-9, which are released from MCs 
upon stimulation by Cath LL-37, are central in promoting rosacea–like skin inflammation. 
Therefore, we anticipated that blocking MC degranulation would also prevent the formation 
of rosacea-like inflammation in the skin. To test this hypothesis, cromolyn sodium, a very 
well known MC stabilizer, was injected intra peritoneal (I.P.) into WT mice (10mg/kg body 
weight, per day) for 4 days before Cath LL-37 challenge. 24 hours after the last cromolyn 
sodium injection, mice were injected with 50 μl of 320 μm Cath LL-37 or PBS, twice a day 
for 2 days. As expected, skin inflammation did not develop in the mice pretreated with 
cromolyn. Mmp9 and Cxcl2 expressions were significantly decreased in the cromolyn 
treated mice (p<0.01) (Figure 3a). Consistent with Mmp9 mRNA expression, MMP activity 
in the tissue was also dramatically decreased by cromolyn pretreatment (p<0.01) (Figure 
3b). In addition, frozen skin sections were stained with anti-MMP-9 and anti-FcεRI 
antibodies for the detection of MCs. The immunostaining images showed that numerous 
MMP-9 positive MCs were observed in Cath LL-37 treated mice, but not in cromolyn 
pretreated Cath LL-37 mice (Figure 3c left panel versus right panel).
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Human MC (huMC) proteases increase keratinocyte expression of LL-37
Because we wanted to understand how human keratinocytes respond to human MCs 
(huMCs), we examined a co-culture of normal human epidermal keratinocytes (NHEK) cells 
with supernatant from huMCs, which had been degranulated by compound 48/80. MMP and 
KLK enzyme activities were significantly increased in NHEK cells when the cells were co-
cultured for 24hrs with 100μL of huMC supernatant (p<0.001) (Figure 3d). Since the 
activation of cathelicidin in keratinocytes requires the active form of vitamin D3, 
1,25(OH)2VD3 (Schauber et al., 2007), we also added 1,25(OH)2VD3 in the co-culture 
model. The Cath LL-37 mRNA (CAMP) level was significantly increased after co-culture 
with huMC supernatant (p<0.001) (Figure 3e).
Therefore, this confirms that, while LL-37 activates MCs, MC supernatants increase 
protease production in human skin epidermis, amplifying the inflammation and creating a 
vicious cycle.
Stabilization of MCs could be a target therapy for erythematotelangiectatic rosacea
To test whether our results were relevant in humans, 10 randomized adults with 
erythematotelangiectatic rosacea were chosen to apply a solution containing either the MC 
stabilizer (4% cromolyn sodium) or placebo, topically to their face, twice daily. Six tape 
strips were obtained from both right and left cheeks, at the time of first visit (v1) and last 
visit (v4). Facial erythema was clinically assessed by a blind investigator using the 
Clinician's Erythema Assessment (CEA). None of the subjects presented with papules and 
pustules; therefore, after eight week (v4), only facial erythema levels decreased in the 
cromolyn treatment group (Data not shown). MMP activity was significantly decreased in 
the cromolyn treatment group (Figure 3f) while KLK activity (Figure 3g) and Cath LL-37 
protein levels (Figure 3h) only showed a mild decrease.
Discussion
An abnormal increase in the free form of hCAP18 (Cath LL-37) antimicrobial peptide in 
human skin is crucial for the pathogenesis of rosacea (Yamasaki et al., 2007). MCs are one 
of the primary sources of cathelicidin in the skin and they are also the main source of 
enzymes that activate cathelicidin to its active form (Cath LL-37) (Di Nardo et al., 2003). 
Previous studies have reported that MC activity increases in the skin of rosacea patients 
(Yamasaki et al., 2007). However, a great number of questions remain regarding the manner 
in which inflammatory signals are transmitted from the epidermis to vessels and 
inflammatory cells. In the present study, we found that MC proteases and Mmp9 mRNAs are 
highly expressed in skin from rosacea patients (Figure 1a). Therefore, we hypothesize that 
after Cath LL-37 has been released from the epidermis in rosacea skin, it in turn activates 
MCs to induce inflammation and neutrophil recruitment, which results in more Cath LL-37.
We next demonstrated that Cath LL-37 peptide strongly activates skin MCs to release 
proteases that are crucial in the development of rosacea-like inflammation in vivo. We 
clearly showed that in MC-deficient mice, intradermal Cath LL-37 injections did not 
generate all of the dermal events that are usually found in rosacea, including inflammation 
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and MMP-9 activation. To more strongly support our hypothesis that MCs are crucial in the 
generation of skin inflammation, we also reconstituted MC deficient mice with WT MCs 
and showed that the rosacea-like inflammation phenotype reappears. Moreover, we 
demonstrated the specificity of Cath LL-37 peptide in MC activation by showing that 
injection of a scrambled peptide did not induce inflammation (Figure 1c). This result is 
nicely paralleled by our in vitro experiments, where we observed an increase in MMP-9 
protease activity in the culture supernatant of Cath LL-37 treated mMCs (Figure 2b). Our 
hypothesis that MMP-9 is involved in rosacea pathogenesis is supported by the recent 
discovery that doxycycline, which is an effective therapeutic for improving rosacea 
symptoms, inhibits MMPs directly (Kanada et al., 2012).
Any signal (especially from neurogenic factors) that induces the activation of MCs results in 
the amplification of the inflammatory response, thus we propose that MCs are the missing 
link between flaring and inflammation in rosacea. Tryptase activates PAR-2 on nerve 
endings and keratinocytes, which in turn causes the release of neuropeptides (Steinhoff et 
al., 1999). On the other hand, activated PAR-2 stimulates MC mediator release (e.g. 
histamine release) during cutaneous inflammation (Aubdool and Brain, 2011). Transient 
receptor potential vanilloid 1 (TRPV1) and ankyrin 1 (TRPA1), which are highly expressed 
on primary sensory neuron endings, are also strongly present in rosacea skin (Aubdool and 
Brain, 2011). Activated PAR-2 enhances these receptors in the vascular endothelial cells and 
immune cells (Aubdool and Brain, 2011), explaining how MCs might be linked to rosacea 
flashing and erythema. PACAP is a neuropeptide that has been shown to be one of the main 
mediators in the response to psychological stress and is abundantly expressed in rosacea-
affected skin (Schwab et al., 2011). It has been reported that PACAP is not only able to 
induce neuronal inflammation, but also edema and flushing in human skin (Roosterman et 
al., 2006). Our in vivo experiments have proven that intradermal injections of PACAP 
significantly induce the expression of the MC proteases, Mmp1a and Mmp9 in WT mice, but 
not in MC deficient mice (Figure 2f). Moreover, dramatically increased expressions of the 
pro-inflammatory cytokines Tnf and Cxcl2 were observed in skin after PACAP challenge 
(Figure 2g). Though it is well known that neuronal activation results in the release of MC-
derived histamine and leukotriene, our study also confirms that PACAP increases the 
expressions of Mmp1 and Mmp9, which are activators of hCAP18 processing to Cath LL-37. 
In our last experiment, we also proved that activated MCs, release enzymes that increase 
LL-37 expression in keratinocytes. Therefore, we have proven a link between PACAP and 
Cath LL-37. Consequently, these peptides work synergistically in the development of 
rosacea symptoms in human skin.
Since MC activation plays an important role in rosacea inflammation, we examined whether 
the stabilization of MCs can directly reduce skin inflammation in WT mice. In our research, 
mice injected I.P. with cromolyn did not develop rosacea-like skin inflammation after Cath 
LL-37 challenge. Moreover, MMP activity, Mmp9 and Cxcl2 mRNA expressions and 
MMP-9/MC immunostaining in the skin were significantly decreased compared with mice 
not treated with cromolyn. Cxcl2 is the mouse homolog of human IL8 and is crucial for 
neutrophil recruitment in vivo.
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Few case reports have cited MC stabilizers as a potential treatment for rosacea and Morbus 
Morbihan (J F Mayberry et al., 1975), (Hu et al., 2012); however, we have now determined 
that MC stabilizers actually block MC induced inflammation and have the potential to be 
developed as therapeutics for the treatment of rosacea. Skin MCs are localized near 
keratinocytes and sensory nerve endings in the epidermis and dermis, therefore, MC 
proteases (chymase and tryptase), histamine, MMP-9 and pro-inflammatory cytokines 
amplify the progression of skin inflammation, tissue remodeling and angiogenesis (Coussens 
et al., 2000). Chymase, a MC specific protease, can not only activate pro-MMP-9 and other 
MMP cascades (Tchougounova et al., 2005), but can also inhibit enzyme degradation by 
TIMP-1, further stabilizing MMP-9. From our observations of the mouse model of rosacea, 
we have proven that pro-inflammatory peptides generated from epidermal keratinocytes and 
sensory nerve endings, activate dermal MCs, that in turn amplify skin inflammation and 
angiogenesis via their secretion of proteases, MMP-9, and pro-inflammatory cytokines. In 
addition, our in vitro data of NHEK cells strongly support the hypothesis that protease 
generated from MCs will induce dermal inflammation and increase the production of 
enzymes from the epidermal layer able to generate LL-37, with the result of creating a pro-
inflammatory loop (Figure 3d and e). Release of MC proteases activate MMP-9 and KLKs 
in NHEK, which results in the generation of additional active Cath LL-37 peptide.
In conclusion, rosacea features cannot be generated in mouse skin in the absence of MCs or 
when MCs have been pharmacologically stabilized. LL-37 and neuropeptides activate MCs; 
activated huMC, in turn, increase NHK expression and processing of LL-37, making huMCs 
central in amplifying rosacea inflammation and symptoms, especially erythema, flushing 
and telangiectasia. Moreover, our preliminary results from a limited clinical trial, supports 
the hypothesis that MC stabilizers can change metalloproteinase activity in rosacea in 
humans. Based on these observations, MC stabilizers should be considered as a future 
therapy in the treatment and prevention of rosacea symptoms.
MATERIALS AND METHODS
Reagents
Mca-Lys-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 fluorogenic substrate and 6-Amidino-2-
naphthy-4-guanidinobenzoate dimethanesulfonate were purchased from Enzo Life Sciences 
(Plymouth Meeting, PA). Cromolyn sodium and substance P fragment were purchased from 
Sigma-Aldrich (St Louis, MO). Adrenomedullin-2 and PACAP were purchased from 
AnaSpec (Fremont, CA). 4-methylumbelliferyl-2-acetamide-2-deoxy-b-D-glucopyranoside 
was purchased from Calbiochem (EMD Millipore; Billerica, MA). MMP-9 specific inhibitor 
I, chymotryptase-specific fluorogenic substrate, and Pierce BCA protein assay kit were 
purchased from Thermo Fisher Scientific (Chicago, IL).
Human specimens
All the procedures involving human subjects were approved by the University of California 
San Diego Institutional Review Board under IRB number 071032 in accordance with 
adherence to the Helsinki Guidelines and written informed patient consent was obtained. 
2mm skin biopsies were taken from the faces of healthy and rosacea subjects, as well as tape 
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strips from the face of erythematotelangiectatic rosacea subjects in the dermatology clinic at 
the University of California, San Diego. Ten randomized adults with 
erythematotelangiectatic rosacea were applied a water-based solution containing either 4% 
cromolyn sodium or placebo, topically to their face twice a day, for 8 weeks. A clinical 
evaluation was performed at each visit. A total of six tape strips were obtained from right 
and left cheek at each of the first visit and the final visit. Facial erythema was clinically 
assessed by a blind investigator using the Clinician's Erythema Assessment (CEA), which 
grades erythema on a five point scale: 0 = none (no redness), 1 = mild (slight pinkness), 2 = 
moderate (definite redness), 3 = significant (marked erythema), 4 = severe (fiery redness). 
At each visit, the CEA was performed on five different facial regions: right cheek, left 
cheek, nose, chin and glabella. The subject's final CEA score for each visit was calculated 
by summing the CEA score of each of the five facial regions for that visit.
Mouse experiments
B6.Cg-KitW-sh/HNihrJaeBsmJ MC deficient mice were bred at our facility. Institutional 
Animal Care and Use Committee (IACUC) of UC San Diego approved all animal 
experiments. B6.Cg-KitW-sh/HNihrJaeBsmJ (KitW-sh) the W-sash (Wsh) inversion mutation 
have MC deficiency, but lack anemia and sterility. Adult KitW-sh mice had a profound 
deficiency in MCs in all tissues examined, but normal levels of major classes of other 
differentiated lymphoid cells. MC deficient mice and wild type mice (C57BL/6) were 
utilized for these experiments. WT and MC deficient mice were shaved 24 hrs before 
intradermal injection with 50 μl of 50 μM or 320 μM of Cath LL-37 or filtered PBS (n=3), 
twice a day for 2days. Skin biopsies were taken after 72 hours of observation and tissues 
were immersed immediately into RNA stabilization reagent (RNAlater; QIAGEN science, 
Germantown, MD). Total RNA was extracted and purified by RNeasy Mini Kit (QIAGEN 
science). mRNA expressions of proteases and cytokines were assessed by RT-PCR. For the 
time course observation of chymase and tryptase mRNAs, skin biopsies of WT and MC 
deficient mice were taken at 1, 4, and 24 hrs after Cath LL-37 injection and analyzed by RT-
PCR.
For the neuropeptide challenge experiment, 0.1 μM neuropeptide or PBS was injected into 
WT mice and MC deficient mice intradermally. Skin biopsies were taken 6 hrs after 
injection and analyzed by RT-PCR.
For the MC stabilizer experiment: Cromolyn sodium (10mg/kg body weight, per day) 
(Sigma-Aldrich, St Louis, MO) was diluted in filtered PBS and injected I.P. into WT mice 
for 4 days. After 4 days of treatment, 50 μl of 320 μM of Cath LL-37 or PBS were injected 
intradermally twice a day for 2 days while continuing daily cromolyn treatment. 72 hrs after 
the beginning of the Cath LL-37 injections, skin biopsies were taken and analyzed for 
mRNA expression and protease activity.
MCs
Primary MCs were generated from mouse bone marrow and cultured in RPMI 1640 medium 
(Invitrogen) supplemented with 10% inactivated FBS (Thermo Fisher Scientific, Chicago, 
IL), 25 mM HEPES (pH 7.4), 4 mM L-glutamine, 0.1 mM nonessential amino acids, 1 mM 
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sodium pyruvate, 50 mM 2-ME, 100 IU/ml penicillin, and 100 mg/ml streptomycin, 
recombinant murine IL-3 (R&D Systems, Minneapolis, MN) and recombinant murine stem 
cell factor (R&D Systems). MMCs derived from bone marrow cells that are cultured with 
SCF and IL-3 become mature in vitro. After 4 weeks, MCs were consistently generated, as 
confirmed by the expression of CD117 (c-Kit) and FcεRI. Cell maturation was confirmed by 
metachromatic staining with toluidine blue. The purity of MCs was greater than 98%. MCs 
were cultured in Stemline® II Hematopoietic Stem Cell Expansion Medium (Sigma-
Aldrich).
BMMC reconstitution in KitW-sh mice
4×106 cells of C57BL/6 mature BMMCs were diluted in filtered PBS and injected into the 
shaved back skin of 6 week old C57BL/6-KitW-sh mice (400 μl; 8 × 50 μl injections) 
intradermally. After 6 weeks, MCs were confirmed as resident cells in skin by toluidine blue 
staining.
Measurement of protease activity
Total-MMP activities were determined in 0.1 M Tris-HCl (pH 7.5) containing 150 mM 
NaCl, 10 mM CaCl2, 0.1 mM ZnCl2, 0.05% (v/v) Brij35, 0.1% (w/v) PEG6000. Protein 
extracts were normalized with a BCA assay kit. Total-MMP activity was determined with 
total-MMP fluorogenic substrate (5 μM): Mca-Lys-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 
(Enzo Life Sciences), in protein extracts, incubated for 2 hrs at 37°C, and subsequently 
measuring activity (Vmax/sec) at a fluorescence excitation wavelength 328 nm and an 
emission wavelength of 400 nm in a fluorescence plate reader (Gemini EM microplate 
spectrofluorometer; Molecular Devices, Sunnyvale, CA). To determine MMP-9 activity, 
MMP-9 specific inhibitor I (Thermo Fisher Scientific, Chicago, IL) was added to protein 
extracts. Chymase and tryptase activities were assayed in 0.1 mM Tris-HCl (pH 8.0), 200 
mM NaCl. Chymase activity was monitored by adding chymotryptase-specific fluorogenic 
substrate (Thermo Fisher Scientific) (5 μM) to protein extracts, incubating for two hours at 
37 °C and subsequently measuring activity (Vmax/sec) at a fluorescence excitation 
wavelength of 380 nm and an emission wavelength of 460 nm. Tryptase activity was 
determined by adding serine protease-specific fluorogenic substrate (Boc-Phe-Ser-Arg-
AMC, Bachem Biosceince Inc.) (5 μM) with/without ABESF (Sigma) to protein extracts, 
incubating for two hours at 37°C, and subsequently measuring relative fluorescence units 
(RFU) at a fluorescence excitation wavelength of 354 nm and an emission wavelength of 
422 nm. Proteins in skin tissues or cells were normalized with the Pierce BCA protein assay 
kit (Thermo Fisher Scientific).
Semi quantitative real-time-PCR
cDNA was synthesized from RNA using the iScript cDNA Synthesis Kit (BioRad, Hercules, 
CA) according to the manufacturer's protocol. Synthesized cDNA was normalized using a 
NanoDrop spectrophotometer (Thermo Fisher Scientific Inc.). TaqMan Gene Expression 
Assays (Applied Biosystems ABI, Foster City, CA) were used to analyze the expressions of 
human MMP9, human CMA1, human CAMP, mouse Mmp9, mouse Mmp1a, mouse Klk5, 
mouse Klk6, mouse Tpsab1, mouse Cma1, mouse Cxcl2 and mouse Tnf as described by the 
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manufacturer's instructions (Applied Biosystems; ABI, Foster City, CA). GAPDH and 
Gapdh mRNA were used as an internal control to validate RNA for each sample. mRNA 
expression was calculated as the relative expression to GAPDH or Gapdh mRNA, and all 
data are presented as fold change of each control.
MC degranulation assay
Degranulation percentage was assessed by measuring the activity of β-hexosaminidase in the 
supernatants of 1×105 MCs in 200 ml Tyrode's buffer incubated for 1 hr with 0 or 20 nM of 
Cath LL-37, 1% Triton X-100 and 10 μg/mL compound 48/80 (Sigma-Aldrich, St Louis, 
MO) as a positive control. For each sample assayed, supernatant aliquots (25 μL) were 
mixed with substrate solution (50 μL), which consisted of 10 mM 4-methylumbelliferyl-2-
acetamide-2-deoxy-b-D-glucopyranoside (Calbiochem; EMD Millipore, Billerica, MA) in 
0.1 M sodium citrate buffer (pH 4.5), and were incubated for 30 min at 37°C. The reaction 
was then stopped by adding 50 μL of 0.4 M glycine (pH 10.7). The reaction mixtures were 
excited at 365 nm and measured at 460 nm in a fluorescence plate reader (Gemini EM 
microplate spectrofluorometer; Molecular Devices, Sunnyvale, CA). To determine the total 
cellular content of this enzyme, an equivalent number of cells were lysed with 1% Triton 
X-100 and 10 μg/mL compound 48/80 (Sigma-Aldrich). Release of β-hexosaminidase was 
calculated as the percentage of the total enzyme content.
Cath LL-37 stimulation of mMCs
mMCs were challenged in vitro with 10ug/mL Cath LL-37. The cells were harvested at 0, 5 
and 24 hours and mRNA was extracted and assessed by RT-PCR for mouse metallo protease 
9 (Mmp9), mouse Chymase (Cma1) and mouse Tryptase (Tpsab1) expression. mMC 
Metalloprotease activity was assessed at 6 and 24 hours after Cath LL-37 challenge as 
previously described. mMC degranulation in response to LL-37 was assessed at 24 hours by 
β-hexosaminidase release as described; positive control (48/80) and negative control (PBS) 
were added. For IL-6 level evalulation, mMcs were treated with 20 and 40nM of LL-37 for 
24 and 48 hours. ELISA (ELISA MAX™ Deluxe; BioLegend, San Diego, CA) was utilized 
to determine mouse IL-6 in all supernatants of cell culture medium according to the 
manufacturer's instructions. All supernatant samples were normalized by Pierce BCA 
protein assay kit (Thermo Fisher Scientific) to total protein content of the sample.
MC supernant–NHEK stimulation
2 days after confluence in Epilife medium (Cascade biologic) with 0.06mM CaCl2, NHEK 
cells were stimulated with supernatant from degranulated human cord blood-derived MCs in 
saline buffer, or saline buffer alone. MMP and KLK protease activities in the NHEK were 
evaluated after 24 hours. RT-PCR was evaluated after 6 hours from the MCs supernatant 
addition. For RTPCR Cath LL-37 mRNA (CAMP) expression, 100nM 1,25(OH)2VD3, was 
added. All of the experiments were repeated at least three times
Fluorescence immunohistochemistry
Mouse skin frozen sections were fixed with acetone, washed in 1X PBS, blocked with 5% 
goat serum/1% BSA for 30 minutes, and incubated with anti-MMP-9 polyclonal antibody 
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(ABBIOTEC, San Diego, CA) as a primary antibody (diluted 1:200). FITC-conjugated goat 
antibody to rabbit IgG (Molecular Probes, Grand Island, NY) was used as a secondary 
antibody (diluted 1:1000) and was incubated for 40 minutes. For FcεRI detection, we used 
anti-mouse FcεRI PE (eBioscience, San Diego, CA). We mounted sections in ProLong Anti-
Fade reagent (Molecular Probes) with 4’, 6-diamidino-2-phenylindole (DAPI). After 
overnight incubation at 4°C in the dark, images were obtained using a Zeiss LSM510 laser 
scanning confocal microscope coupled with an Axiovert 100 inverted stage microscope.
Statistical analyses
The data are presented as means ±SEM. To determine the significance between two or more 
groups, one-way and two-way ANOVA or the two-tailed t test was used and analyzed by 
GraphPad Prism4 (GraphPad Software, Inc.). For all statistical tests, p<0.05 was considered 
statistically significant.
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Figure 1. (a-e) MC proteases and MMP-9 are crucial for rosacea inflammation development
(a) Human biopsy samples from healthy subjects (n=6) and rosacea subjects (n=6) were 
assessed for CMA1 and MMP9 mRNA expressions. (b) The back skins of wild type 
C57BL/6 (WT) and MC-deficient (KitW-sh) mice were injected intradermally with Cath 
LL-37. Pictures were taken 72 hours after LL-37 injections. (c) RT-PCR of Mmp9 mRNA 
expression in skin biopsies from WT, WT MC reconstituted KitW-sh (KitWsh) and KitW-sh. 
Mouse skin was injected with LL-37, LL-37 scrambled peptide (LL-37 Scr) or PBS control 
(PBS) and harvested after 72 hours of observation. (d) Assessment of MMP protease 
activity in WT mouse skin following challenge with PBS or Cath LL-37 at 50 and 320 μM. 
(e) mouse Chymase (Cma1) and mouse Tryptase (Tpsab1) were analyzed by RT-PCR in the 
skin from WT or KitW-sh mice (KitWsh) at 0, 1, 4, and 24 hrs after Cath LL-37 challenge. 
All of the experiments were repeated at least three times. Statistics: Mann Whitney test, one-
way and two-way ANOVA*p<0.05, **p<0.01, ***p<0.001 (n=3)
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Figure 2. (a-e) Cath LL-37 induces pro-inflammatory responses
(a) in vitro mMCs expression of Metallo protease 9 (Mmp9), Chymase (Cma1) and 
Tryptase (Tpsab1) after Cath LL-37 stimulation. (b) mMC Metallo pretease activity (MMP 
protease activity) after Cath LL-37 challenge. (c) mMCs degranulation (as β 
hexosaminidase release) in response to 24 hrs treatment with 20nM LL-37, positive control 
(48/80) and negative control (PBS). (d) ELISA IL-6 level (as pg/ml per million MCs) in 
mMC culture, 24 and 48 hours after 20 and 40 nM LL-37 treatment. (e) In vivo Il6 mRNA 
expression in mouse skin after 0, 1, 4, and 24 hrs of Cath LL-37 challenge in WT and MC 
deficient mice (KitWsh). (f-g) Neuropeptide-induced pro-inflammatory cytokine expression 
in skin is decreased in the absence of MCs in KitW-shmice. WT and KitW-sh (KitWsh), 
mice were injected with PBS or neuropeptide (SP, substance P; ADM-2, adrenomedullin-2; 
PACAP, pituitary adenylate cyclase-activating peptide) intradermally. (f) mRNA 
expressions of mouse Chymase (Cma1), mouse Tryptase (Tpsab1), mouse metalloprotease 9 
(Mmp9), and metalloprotease 1 (Mmp1a) after NP challenge. (g) mRNA expressions of 
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proinflammatory cytokines (Cxcl2 and Tnf) after NP challenge. Statistics: two-way 
ANOVA*p<0.05, **p<0.01, ***p<0.001 (n=3) repeated 3 times.
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Figure 3. (a-c) Cromolyn treatment of the rosacea-mouse model
Mice were treated with Cromolyn (C) or Cromolyn and LL-37 (C+LL-37). (a) Skin mRNA 
expression of mouse metalloprotease 9 (Mmp9) and pro-inflammatory cytokine (Cxcl2). (b) 
Skin Metalloproteases total activity (MMP activity). (c) Mouse skin immunohistochemistry 
of mMC-MMP9 contents after LL-37 challenge (left image, LL-37) and cromolyn pre-
treatment LL-37-challenge (right image, C+LL-37). MMP-9 (green), FcεRI (Red: MC 
marker) and DAPI (Blue: cell nuclei). Yellow –orange hue indicates MMP9 and mMC co-
localization. Yellow orange color is not present in the right image. Scale bar = 50.0μm. (d-e) 
MC degranulation increases protease activity in NHEK. (d) MMP and KLK protease 
activities in NHEK after addition of the product of huMC degranulation in saline buffer 
(+Sup), or saline buffer (+Saline). (e) RT-PCR Cath LL-37 mRNA (CAMP) expression in 
NHEK cells treated with the product of huMC degranulation in saline buffer and 
1,25(OH)2VD3 (Sup+VD), or saline buffer and 1,25(OH)2VD3 (Saline+VD) and saline 
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alone (Saline); (f-h) Cromolyn effect on protease activity of rosacea patients. (f) MMP 
activity on the skin of patient treated with placebo (n=5) or cromolyn (n=5) (g) KLK 
activity. (h) LL-37 peptide level. Statistics: ***p<0.001, **p<0.01, *p<0.05
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